Xilio Therapeutics, Inc.
XLONASDAQHealthcare● Active
$7.68
$-0.02(-0.26%)
Market Cap$45948204
P/E Ratio—
52W High$12.74
52W Low$6.468
Xilio Therapeutics, Inc. (XLO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
XLO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.58
Est. -$0.66 · +12.1%
Revenue
$0.01B
Est. $0.01B · +48.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 7-Quarter EPS Beat Streak
XLO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.59 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$0.66 | -$0.58 | +12.1% | $0.01B | $0.01B | +48.5% |
| ▲ Q1 FY2026 | Mar 23, 2026 | -$1.68 | -$0.85 | +49.4% | $0.01B | $0.01B | +25.6% |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.45 | -$0.03 | +93.3% | $0.02B | $0.02B | +2.3% |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$1.10 | -$0.16 | +85.5% | $0.01B | $0.02B | -56.6% |
| ▲ Q2 FY2025 | May 8, 2025 | -$2.70 | -$0.18 | +93.3% | $0.00B | $0.02B | -87.4% |
| ▲ Q1 FY2025 | Mar 11, 2025 | -$3.03 | -$0.20 | +93.4% | $0.00B | $0.02B | -92.6% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.25 | -$0.22 | +12.0% | $0.00B | $0.00B | -31.4% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.59
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.58
EPS Est.
-$0.66
EPS Surpr.
+12.1%
Revenue
$0.01B
Q1 FY2026
Mar 23, 2026Beat
EPS Actual
-$0.85
EPS Est.
-$1.68
EPS Surpr.
+49.4%
Revenue
$0.01B
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.03
EPS Est.
-$0.45
EPS Surpr.
+93.3%
Revenue
$0.02B
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.16
EPS Est.
-$1.10
EPS Surpr.
+85.5%
Revenue
$0.01B
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.18
EPS Est.
-$2.70
EPS Surpr.
+93.3%
Revenue
$0.00B
Q1 FY2025
Mar 11, 2025Beat
EPS Actual
-$0.20
EPS Est.
-$3.03
EPS Surpr.
+93.4%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.22
EPS Est.
-$0.25
EPS Surpr.
+12.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.92 | $-0.92 | $-0.92 | 1 |
| Q3 FY2027 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q2 FY2027 | $-0.84 | $-0.84 | $-0.84 | 1 |
| Q1 FY2027 | $-0.81 | $-0.81 | $-0.81 | 1 |
| Q4 FY2026 | $-0.92 | $-0.92 | $-0.92 | 1 |
| Q3 FY2026 | $-0.92 | $-0.92 | $-0.92 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +12.1% | $7.73 | $7.73 | +0.00% |
| ▲ Q1 FY2026 | Mar 23, 2026 | +49.4% | $7.86 | $7.86 | +0.00% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +93.3% | $10.83 | $9.82 | -9.33% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +85.5% | $10.01 | $9.84 | -1.70% |
| ▲ Q2 FY2025 | May 8, 2025 | +93.3% | $9.33 | $10.08 | +8.04% |
| ▲ Q1 FY2025 | Mar 11, 2025 | +93.4% | $11.83 | $11.10 | -6.17% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +12.0% | $18.06 | $14.56 | -19.38% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -4.3% | $12.06 | $12.03 | -0.25% |
Q2 FY2026+0.00%
Report Date
May 12, 2026
EPS Beat/Miss
+12.1%
Price Before
$7.73
Price After
$7.73
Q1 FY2026+0.00%
Report Date
Mar 23, 2026
EPS Beat/Miss
+49.4%
Price Before
$7.86
Price After
$7.86
Q4 FY2025-9.33%
Report Date
Nov 13, 2025
EPS Beat/Miss
+93.3%
Price Before
$10.83
Price After
$9.82
Q3 FY2025-1.70%
Report Date
Aug 14, 2025
EPS Beat/Miss
+85.5%
Price Before
$10.01
Price After
$9.84
Q2 FY2025+8.04%
Report Date
May 8, 2025
EPS Beat/Miss
+93.3%
Price Before
$9.33
Price After
$10.08
Q1 FY2025-6.17%
Report Date
Mar 11, 2025
EPS Beat/Miss
+93.4%
Price Before
$11.83
Price After
$11.10
Q4 FY2024-19.38%
Report Date
Nov 7, 2024
EPS Beat/Miss
+12.0%
Price Before
$18.06
Price After
$14.56
Q3 FY2024-0.25%
Report Date
Aug 8, 2024
EPS Beat/Miss
-4.3%
Price Before
$12.06
Price After
$12.03
Avg Beat Reaction-4.08%
Avg Miss Reaction-0.25%
Beat Rate7 / 8 quarters
Largest Move-19.38% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: XLO ends December
Xilio Therapeutics, Inc. (XLO) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.58 — beating the analyst consensus of $-0.66 by +12.1%. XLO has beaten EPS estimates for 7 consecutive quarters. The next XLO earnings date is expected around September 1, 2026.
Each quarter, investors track XLO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. XLO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
XLO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
XLO earnings · 5 questionsXilio Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. XLO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; XLO historically reports after market close (AMC).
XLO earnings datewhen is XLO earningsXLO next earnings datewhen does XLO report earningsXLO earnings calendar
▸ Source: FMP · Xilio Therapeutics, Inc. SEC filings · US GAAP · Xilio Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026